Objective To compare the efficacy and pharmacoeconomics of Vonoprazan Fumarate tablets versus Rabeprazole enteric-coated capsules on the treatment of gastroesophageal reflux.Methods A total of 2,000 patients with gastroesophageal reflux disease in our hospital from February 2018 to October 2021 were selected.They were randomly divided into control group and study group,with 1,000 cases per group.Patients in the control group were medicated by Rabeprazole enteric-coated capsules,and those in the study group were medicated by Vonoprazan Fumarate tablets.The therapeutic effect on gastroesophageal reflux,basal acid output,incidence of adverse events,cost-effectiveness ratio of the two groups were compared.Results The treatment effective rate in the study group was significantly higher than that of the control group(P<0.05).The basal acid output in the study group was significantly lower than that of the control group(P<0.05).The disappearance time of regurgitation,abdominal pain,acid regurgitation and belching in the study group was significantly shorter than that of the control group(P<0.05).The incidence of adverse events in the study group was significantly lower than that of the control group(P<0.05).The pharmacoeconomic cost-effectiveness of Rabeprazole enteric-coated capsules was significantly higher than that of Vonoprazan Fumarate tablets.Conclusion Vonoprazan Fumarate tablets are superior to Rabeprazole enteric-coated capsules on the treatment of gastroesophageal reflux in the therapeutic efficacy,basal acid output and lower incidence of adverse events.However,the pharmacoeconomic cost-effectiveness of Rabeprazole enteric-coated capsules is significantly higher than that of Vonoprazan Fumarate tablets.
维普
万方数据
